德尔塔

产品 文章

您当前所在位置：首页 > 最新产品 > 库存现货

最新产品

无机纳米
德尔塔定制
光电化学
热门产品
热销推荐
客户推荐
库存现货
「同位素标记抑制剂」N-Acetyl-D-mannosamine-13C-1

「同位素标记抑制剂」N-Acetyl-D-mannosamine-13C-1

作者：德尔塔生物 日期：2025-06-10

生物活性：N-Acetyl-D-mannosamine-13C-1 is the 13C labeled N-Acetyl-D-mannosamine. N-Acetyl-D-mannosamine (ManNAc) is an essential precursor of N-acetylneuraminic acid (NeuAc), the specific monomer of bacterial capsular polysialic acid (PA)[1][2]体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.N-Acetyl-D-mannosamine-13C-1 相关抗体:MRP2 AntibodyElongation factor 2 Antibody (YA962)Elongation factor 2 Antibody (YA964)PU.1/SPI1 Antibody (YA1116)Sulfadimidine Antibody (YA906)Elongation factor 2 Antibody (YA963)Anthrax Protective gen Antibody (YA1060)Elongation factor 1 gamma Antibody (YA2004)Pulmonary Surfactant Associated Protein D Antibody (YA2107)Cathelicidin Antibody (YA2380)Elongation Factor Ts Antibody (YA2524)Elongation Factor 1A2 Antibody (YA2879)BPI Antibody (YA3068)MetRS Antibody (YA3196)分子量：222.20Formula：C713CH15NO6非标记 CAS：3615-17-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (530 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-21

「同位素标记抑制剂」N-Acetyl-D-mannosamine-13C

「同位素标记抑制剂」N-Acetyl-D-mannosamine-13C

作者：德尔塔生物 日期：2025-06-10

生物活性：N-Acetyl-D-mannosamine-13C is the 13C labeled N-Acetyl-D-mannosamine. N-Acetyl-D-mannosamine (ManNAc) is an essential precursor of N-acetylneuraminic acid (NeuAc), the specific monomer of bacterial capsular polysialic acid (PA)[1][2]体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.N-Acetyl-D-mannosamine-13C 相关抗体:MRP2 AntibodyElongation factor 2 Antibody (YA962)Elongation factor 2 Antibody (YA964)PU.1/SPI1 Antibody (YA1116)Sulfadimidine Antibody (YA906)Elongation factor 2 Antibody (YA963)Anthrax Protective gen Antibody (YA1060)Elongation factor 1 gamma Antibody (YA2004)Pulmonary Surfactant Associated Protein D Antibody (YA2107)Cathelicidin Antibody (YA2380)Elongation Factor Ts Antibody (YA2524)Elongation Factor 1A2 Antibody (YA2879)BPI Antibody (YA3068)MetRS Antibody (YA3196)分子量：222.20Formula：C713CH15NO6非标记 CAS：3615-17-6运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [

「同位素标记抑制剂」D-Lyxose-d-1

「同位素标记抑制剂」D-Lyxose-d-1

作者：德尔塔生物 日期：2025-06-10

生物活性：D-Lyxose-d-1 is the deuterium labeled D-Lyxose. D-Lyxose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Lyxose-d-1 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：151.14Formula：C5H9DO5非标记 CAS：1114-34-7运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (519 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

「同位素标记抑制剂」D-Allose-13C-2

「同位素标记抑制剂」D-Allose-13C-2

作者：德尔塔生物 日期：2025-06-10

生物活性：D-Allose-13C-2 is the 13C labeled D-Allose. D-Allose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Allose-13C-2 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：181.15Formula：C513CH12O6非标记 CAS：2595-97-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

「同位素标记抑制剂」D-Allose-13C-1

「同位素标记抑制剂」D-Allose-13C-1

作者：德尔塔生物 日期：2025-06-10

生物活性：D-Allose-13C-1 is the 13C labeled D-Allose. D-Allose is an endogenous metabolite[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.D-Allose-13C-1 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：181.15Formula：C513CH12O6非标记 CAS：2595-97-3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (520 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]

「同位素标记抑制剂」Tiludronate-d5 sodium

「同位素标记抑制剂」Tiludronate-d5 sodium

作者：德尔塔生物 日期：2025-06-10

生物活性：Tiludronate-d5 (sodium)mis the deuterium labeled Tiludronate disodium. Tiludronate (Tiludronic Acid) disodium, an orally active bisphosphonate, can act an osteoregulator. Tiludronate is used for the research of the metabolic bone disorders. Tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. Antiresorptive and anti-inflammatory properties[1][2][3][4].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Tiludronate-d5 sodium 相关抗体:PMCA1 Antibody (YA1676)分子量：367.60Formula：C7H2D5ClNa2O6P2S非标记 CAS：149845-07-8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (536 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief][2]. Reginster JY, et al. Prevention of postmenopausal bone loss by tiludronate. Lancet. 1989 Dec 23-30;2(8678-8679):1469-71. [Content Brief][3]. Nunes NLT, et al. Effects of local administration of tiludronic acid on experimental periodontitis in diabetic rats. J Periodontol. 2018 Jan;89(1):

「同位素标记抑制剂」Regadenoson-d3

「同位素标记抑制剂」Regadenoson-d3

作者：德尔塔生物 日期：2025-06-10

生物活性：Regadenoson-d3 is the deuterium labeled Regadenoson. Regadenoson (CVT-3146) is a potent and selective A2A adenosine receptor agonist, with Kis of 290 and 1120 nM for rat and pig adenosine A2A receptor, respectively. Regadenoson is selective for the adenosine A2A receptor over adenosine A1 and A2B receptors, and shows 13-fold selectivity over the human adenosine A1 receptor. Regadenoson is a vasodilator stress agent has shifted the landscape of vasodilator myocardial perfusion imaging. Regadenoson increases blood-brain barrier (BBB) permeability in rodents[1][2][3].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Regadenoson-d3 相关抗体:Dopamine Transporter AntibodyAdenosine A1 Receptor Antibody (YA3341)分子量：393.37Formula：C15H15D3N8O5非标记 CAS：313348-27-5中文名称：瑞加德松 d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (531 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief][2]. Jackson S, et al. The effect of regad

「同位素标记抑制剂」Cinacalcet-d3

「同位素标记抑制剂」Cinacalcet-d3

作者：德尔塔生物 日期：2025-06-10

生物活性：Cinacalcet-d3 is the deuterium labeled Cinacalcet. Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Cinacalcet-d3 相关抗体:BNSP AntibodyFACL4 AntibodyBrdU Antibody (YA578)GAPDH AntibodyGlucose 6 Phosphate Dehydrogenase AntibodyMETTL3 AntibodyTSG101 AntibodyAlkaline Phosphatase AntibodyCalnexin Antibody (YA573)Lamin A/C AntibodyLamin B1 AntibodyLAMP1 AntibodyLAMP2 Antibody (YA713)LAMP2a AntibodyNQO1 Antibody (YA697)NQO1 Antibody (YA261)OPA1 AntibodyRBM3 AntibodySynaptophysin Antibody (YA043)Laminin beta 1 AntibodyHeme Oxygenase 1 AntibodyKi67 Antibody (YA717)Ki67 Antibody (YA322)Asparagine Synthetase AntibodyCalnexin AntibodyKi67 Antibody (YA001)Osteopontin AntibodySynaptophysin Antibody (YA664)TREM2 AntibodyGAPDH Antibody (YA848)分子量：360.43Formula：C22H19D3F3N非标记 CAS：226256-56-0中文名称：西那卡塞 d3运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (522 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Su

「同位素标记抑制剂」Levocetirizine-d4 dihydrochloride

「同位素标记抑制剂」Levocetirizine-d4 dihydrochloride

作者：德尔塔生物 日期：2025-06-10

生物活性：Levocetirizine-d4 (dihydrochloride) is the deuterium labeled Levocetirizine. Levocetirizine ((R)-Cetirizine) is a third-generation peripheral H1-receptor antagonist. Levocetirizine is an antihistaminic agent which is the R-enantiomer of Cetirizine. Levocetirizine has a higher affinity for the histamine H1-receptor than (S)-Cetirizine and can effectively treat allergic rhinitis and chronic idiopathic urticaria[1].IC50 & Target：H1 Receptor体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Levocetirizine-d4 dihydrochloride 相关抗体:ADGRE1 (F4/80) Antibody (YA002)ADGRE1 (F4/80) Antibody (YA920)分子量：465.83Formula：C21H23D4Cl3N2O3非标记 CAS：130018-77-8中文名称：左西替利嗪-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (528 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief][2]. Lohar P, et al. Simultaneous bioanalysis and pharmacokinetic interaction study of acebrophylline, levocetirizine and pranlukast in Sprague-Dawley ra

「同位素标记抑制剂」Tazarotene-d8

「同位素标记抑制剂」Tazarotene-d8

作者：德尔塔生物 日期：2025-06-10

生物活性：Tazarotene-d8 is the deuterium labeled Tazarotene. Tazarotene (AGN 190168) is a selective retinoic acid receptor (RAR) agonist for the treatment of plaque psoriasis and acne vulgaris[1][2].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Tazarotene-d8 相关抗体:Retinoid X Receptor alpha Antibody分子量：359.51Formula：C21H13D8NO2S非标记 CAS：118292-40-3中文名称：他扎罗汀 d8运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (527 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.  [Content Brief][2]. Talpur R, et al. Efficacy and safety of topical tazarotene: a review. Expert Opin Drug Metab Toxicol. 2009 Feb;5(2):195-210. [Content Brief][3]. Nagpal S, et al. Negative regulation of two hyperproliferative keratinocyte differentiation markers by a retinoic acidreceptor-specific retinoid: insight into the mechanism of retinoid action in psoriasis. Cell Growth Differ. 1996 Dec;7(12):1783-91. [Content Brief][4]. Tang-Liu DD, et al. Clinical pharmacoki

「同位素标记抑制剂」Buformin-d9 hydrochloride

「同位素标记抑制剂」Buformin-d9 hydrochloride

作者：德尔塔生物 日期：2025-06-10

生物活性：Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Buformin-d9 hydrochloride 相关抗体:AMPK alpha AntibodyPhospho-AMPK alpha 2 (Thr172) AntibodyAMPK alpha 2 Antibody (YA833)Phospho-AMPK alpha 2(Ser345) AntibodyAMPK alpha 1 AntibodyAMPK alpha 1 Antibody (YA624)Phospho-AMPK alpha 1 (Ser496) Antibody (YA226)Phospho-Hormone sensitive lipase (Ser853) AntibodyATF4 Antibody (YA605)AMPK alpha 2 Antibody (YA623)AMPK beta 1 AntibodyAMPK gamma 1 AntibodyATF4 AntibodyPhospho-AMPK alpha 1 (Ser496) AntibodyMARK2 Antibody (YA2104)MARK3 Antibody (YA2150)Phospho-Hormone Sensitive Lipase (Ser855) Antibody (YA2599)分子量：202.73Formula：C6H7D9ClN5非标记 CAS：692-13-7中文名称：丁双胍盐酸盐-d9；1-丁基双胍盐酸盐-d9；丁福明盐酸盐-d9；丁二胍盐酸盐-d9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the pro

「同位素标记抑制剂」Avizafone-d5 dihydrobromide

「同位素标记抑制剂」Avizafone-d5 dihydrobromide

作者：德尔塔生物 日期：2025-06-10

生物活性：Avizafone-d5 (dihydrobromide) is the deuterium labeled Avizafone dihydrobromide[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.分子量：596.79Formula：C23H25D5Br2ClN3O3非标记 CAS：65617-86-9运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (517 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

「同位素标记抑制剂」Acetophenazine-d4 dimaleate

「同位素标记抑制剂」Acetophenazine-d4 dimaleate

作者：德尔塔生物 日期：2025-06-10

生物活性：Acetophenazine-d4 (dimaleate) is the deuterium labeled Acetophenazine dimaleate[1].体外研究(In Vitro)：Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].德尔塔生物 has not independently confirmed the accuracy of these methods. They are for reference only.Acetophenazine-d4 dimaleate 相关抗体:DRD2 AntibodyDopamine Receptor D3 Antibody (YA1742)DOPA Decarboxylase Antibody (YA2428)Dopamine Receptor D1 Antibody (YA3270)Torsin 1A Antibody (YA2935)PITX3 Antibody (YA2974)HMBS Antibody (YA3061)分子量：647.73Formula：C31H33D4N3O10S非标记 CAS：2751-68-0运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (524 KB)产品使用指南 (1538 KB)参考文献[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]

「同位素标记抑制剂」Vortioxetine-d8 hydrobromide

「同位素标记抑制剂」Vortioxetine-d8 hydrobromide

作者：德尔塔生物 日期：2025-06-10

生物活性：Vortioxetine-d8 (Lu AA 21004-d8) hydrobromide is the deuterated form of Vortioxetine. Vortioxetine (Lu AA 21004) is an antagonist of 5-HT3A and 5-HT7 receptors (Ki: 3.7 nM, 19 nM) and an inhibitor of 5-hydroxytryptamine transporter (SERT) (Ki: 1.6 nM), as well as a 5-HT1A agonist and a partial 5-HT1B agonist (Ki: 15 nM, 33 nM)[1].分子量：387.41Formula：C18H15D8BrN2S非标记 CAS：960203-27-4中文名称：沃替西汀 d8 (氢溴酸盐)运输条件：Room temperature in continental US; may vary elsewhere.储存方式：Please store the product under the recommended conditions in the Certificate of Analysis.纯度 & 产品资料Data Sheet (529 KB)产品使用指南 (1538 KB)参考文献[1]. Bang-Andersen B, et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. [Content Brief]

「同位素标记抑制剂」Enclomiphene-d4 hydrochloride

「同位素标记抑制剂」Enclomiphene-d4 hydrochloride

作者：德尔塔生物 日期：2025-06-10

生物活性：Enclomiphene-d4 hydrochloride is a deuterium labeled Enclomiphene hydrochloride. Enclomiphen hydrochloride is a potent and orally active estrogen receptor antagonist with antioestrogenic property[1].IC50 & Target：IC50: Oestrogen Receptor[1]分子量：446.45Formula：C26H25D4Cl2NO非标记 CAS：15690-57-0性状：固体颜色：White to off-white中文名称：恩氯米芬盐酸盐-d4运输条件：Room temperature in continental US; may vary elsewhere.储存方式：-20°C, protect from light, stored under nitrogen*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)纯度 & 产品资料纯度： ≥99.0%参考文献[1]. Fontenot GK, et al. Differential effects of isomers of clomiphene citrate on reproductive tissues in male mice. BJU Int. 2016 Feb;117(2):344-50. [Content Brief]